Phase I Open-Label of Talazoparib on Cardiac Patients

To evaluate the effect of talazoparib on cardiac repolarization in patients with advanced solid tumors by assessing the QTc To assess the relationship between plasma talazoparib concentrations and the QTc

November 16, 2016